Hook & thesis
Kamada Ltd. (KMDA) is a specialty plasma-derived therapeutics company that, over the last 18 months, has turned stronger commercial execution into meaningful margin expansion. KEDRAB/KAMRAB and the broader proprietary products portfolio contributed scale in 2025, and management has followed up with operational investments that should raise recurring revenue from normal source plasma (NSP) sales.
We view the current price of $8.18 as an attractive entry point to add exposure to a company with a combination of: sizable product sales (>$70 million from rabies immunoglobulin in 2025), improving adjusted EBITDA trends, low leverage and several near-term catalysts that can re-rate the stock. Our trade plan: Buy at $8.10, target $9.50 and stop loss $7.25, mid-term (45 trading days).
What Kamada does and why it matters
Kamada is a biopharmaceutical company focused on plasma-derived specialty therapies and a distribution arm that commercializes in-licensed third-party products. The business is structured around two economically complementary segments:
- Proprietary Products - plasma-derived therapies, including rabies immunoglobulins KEDRAB and KAMRAB, plus normal source plasma (NSP) sales from company-operated collection centers.
- Distribution - commercialization and distribution of third-party pharmaceutical products in select markets.
Why the market should care: plasma therapies are sticky, high-margin products with long development timelines for competitors; owning collection capacity provides a margin tailwind as Kamada internalizes plasma supply. Recent FDA approvals expand both manufacturing/testing and collection capacity in the U.S., which should convert to recurring NSP revenue and insulate margins.
Supporting data points
- Current share price: $8.18; market cap approximately $467.8 million with ~57.7 million shares outstanding.
- Reported product sales momentum: the rabies immunoglobulin products (KEDRAB and KAMRAB) generated over $70 million in sales in 2025.
- Q3 2025 operational performance: revenues of $47.0 million (up 13% year-over-year) and adjusted EBITDA of $11.7 million (up 34%).
- Valuation multiples on snapshot data: price-to-earnings around 18.8x and price-to-book about 1.75x, with enterprise value roughly $464 million.
- Balance sheet and liquidity: low reported leverage (debt-to-equity ~0.03), conservative working capital (current ratio ~3.55, quick ratio ~2.24), though free cash flow has been negative recently (-$8.12 million) as capacity investments progress.
- Technicals and market structure: 10/20/50-day moving averages cluster around the mid-$7s to low-$8s, RSI ~56 and MACD showing bullish momentum; short interest has been modest in absolute terms (recent days-to-cover ~2.6), which implies manageable squeeze risk but potential volatility.
Why fundamentals justify a Buy
1) Durable product base with scale: The rabies immunoglobulin franchise produced >$70M in 2025 sales, representing a large and recurring revenue stream for a company of this size. That revenue base provides both cash generation and visibility.
2) Operational expansion that adds low-cost supply and margin upside: FDA approval of a new in-house rabies testing laboratory (RFFIT) on 06/01/2026 and the San Antonio plasma collection center approval on 03/26/2026 materially improve control over quality and plasma input. The San Antonio site has planned capacity around 50,000 liters/year and management guidance suggests incremental NSP revenue potential of $8-10 million annually at full capacity.
3) Improving profitability metrics: Management reported strong adjusted EBITDA growth in Q3 2025 (+34% y/y), showing the company can leverage fixed costs and scale sales into higher margin outcomes. With low financial leverage, incremental EBITDA flow-through can disproportionately benefit equity value.
Valuation framing
On headline multiples the stock trades at roughly 18.8x reported P/E and a price-to-book near 1.75x. With a market cap of about $467.8M and enterprise value about $464M, the market is pricing in steady revenues and modest margin expansion but not a dramatic acceleration. Considering the company already generates >$70M from its core products and is scaling NSP revenues via its U.S. collection footprint, the multiple appears reasonable to inexpensive versus the growth and margin optionality embedded in new capacity and testing capabilities.
Two important qualifiers: free cash flow was negative recently (-$8.12M) as investments were made, and EV/EBITDA is distorted by accounting timing. Still, the combination of low leverage, improving adjusted EBITDA and concrete revenue contributions from approved facilities supports a move higher in the multiple if execution continues.
Catalysts
- Full ramp-up of the San Antonio plasma center - expected to contribute ~$8-10M at full capacity; early ramp commentary would be a positive trigger.
- Commercial momentum for KEDRAB/KAMRAB and continued stability or growth in rabies immunoglobulin sales (>$70M in 2025 is the baseline).
- Operational cost improvements from bringing rabies testing in-house after FDA approval of the RFFIT lab (06/01/2026), which can shorten lead times and reduce third-party fees.
- Management communications at the H.C. Wainwright conference (presentation on 09/15/2026) or upcoming quarterly releases where management provides updated guidance on NSP and distribution growth.
- Potential M&A or licensing deals that leverage Kamada's distribution footprint and fill product pipeline gaps.
Trade plan (actionable)
We upgrade KMDA to a Buy and lay out a mid-term swing trade with defined risk management:
- Entry: Buy at $8.10.
- Target: $9.50 (near-term upside toward and slightly above the 52-week high of $9.35).
- Stop loss: $7.25.
- Horizon: mid term (45 trading days). We choose 45 days to allow time for operational updates and early ramp indicators from the San Antonio center or quarterly commentary to materialize. If a near-term catalyst (earnings release or conference commentary) accelerates momentum, consider scaling out at the target; if the business shows upside endurance, re-evaluate for a longer hold.
Position sizing & management
Given the stock's volatility profile, short interest and recent average volumes (two-week average ~159,872 shares/day), position size should be scaled so that the move from entry to stop represents a comfortable capital-at-risk allocation. Tight stop discipline is critical here because the company remains in an investment phase with negative recent free cash flow.
Risks and counterarguments
- Execution risk on capacity ramp: The San Antonio center's revenue projection of $8-10M at full capacity assumes successful ramp and donor recruitment; delays or lower-than-expected yields would compress near-term upside.
- Cash flow pressure from investments: Free cash flow was negative (~-$8.12M) as the company invested in testing and collection capacity. If profitability improvements do not offset capex, the valuation could come under pressure.
- Regulatory and quality risk: Plasma businesses are subject to intensive regulatory oversight; adverse findings or product recalls would be highly damaging to revenue and margins.
- Reimbursement and pricing pressure: Plasma-derived products depend on healthcare reimbursement and purchasing dynamics; any downward pressure on pricing or shifts in payer behavior could blunt revenue growth.
- Concentration and single-product sensitivity: While the rabies immunoglobulin franchise is a strength (>$70M in 2025), heavy reliance on a few products increases vulnerability to competitive or regulatory events affecting those products.
- Counterargument: The stock's headline multiples (P/E ~18.8x) already reflect some growth expectation and the market may be cautious because of recent negative free cash flow and investment-phase dynamics. If sales growth stalls or adjusted EBITDA retraction occurs, the valuation can decompress quickly.
What would change our view
We would become more bullish if management reports sustained quarter-over-quarter revenue growth above guidance, clear margin expansion (continued adjusted EBITDA improvement), and visible early revenue from the San Antonio center. Conversely, we would downgrade the trade if a) free cash flow remains materially negative beyond the expected investment payback period, b) there are regulatory or quality issues at any of the production or collection sites, or c) rabies immunoglobulin sales decline materially from the 2025 baseline.
Bottom line
Kamada is a well-capitalized, low-leverage plasma therapeutics company with a sizable core franchise and concrete capacity expansion that should lift recurring NSP revenue. The company has demonstrated margin improvement and has several catalysts that can re-rate the multiple. We are upgrading to Buy and recommend a mid-term trade at $8.10 with a target of $9.50 and a stop at $7.25. Keep strict risk management in place: the business is still in an investment phase and execution matters.
Key near-term dates to watch: Q1 2026 financial releases and conference calls, management presentations at investor conferences, and commercial updates on the ramp of the San Antonio plasma collection center and internal testing lab deployment (RFFIT).